



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:

Alderson *et al.*

Appl. No.: 09/499,468

Filed: February 7, 2000

For: **Use of Vascular Endothelial  
Growth Factor to Treat  
Photoreceptor Cells (as amended)**

Confirmation No.: 1320

Art Unit: 1647

Examiner: Landsman, Robert S.

Atty. Docket: 1488.100000F/PAJ/PAC

**Fifteenth Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(b)**

*Mail Stop RCE*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08A, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fifteenth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fourteenth Supplemental Information Disclosure Statement filed on April 26, 2006 in connection with the above-captioned application.

Copies of documents FP14 to FP19 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents US12 to US26, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Form based on information presently available to the undersigned. However, the listed publication dates

should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Form, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Paul A. Calvo  
Agent for Applicants  
Registration No. 57,913

Date: 9/2/06  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
576160v1



<b>FIFTEENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/499,468
				Filing Date	February 7, 2000
				First Named Inventor	Ralph Alderson
				Art Unit	1647
Sheet	1	of	1	Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.100000F/PAJ/PAC

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	US12	6,297,238	10/02/2001	Doyle <i>et al.</i>	
	US13	6,515,105	02/04/2003	Alitalo <i>et al.</i>	
	US14	6,660,744	12/09/2003	Hirst <i>et al.</i>	
	US15	6,713,474	03/30/2004	Hirst <i>et al.</i>	
	US16	2002/0019350 A1	02/14/2002	Levine <i>et al.</i>	
	US17	2002/0086004 A1	07/04/2002	Adnot <i>et al.</i>	
	US18	2002/0111362 A1	08/15/2002	Rubinfeld, Joseph	
	US19	2002/0156081 A1	10/24/2002	Hirst <i>et al.</i>	
	US20	2003/0125523 A1	07/03/2003	Alitalo <i>et al.</i>	
	US21	2003/0153752 A1	08/14/2003	Hirst <i>et al.</i>	
	US22	2003/0187001 A1	10/02/2003	Calderwood <i>et al.</i>	
	US23	2003/0211988 A1	11/13/2003	Epstein, Stephen E.	
	US24	2004/0002140 A1	01/01/2004	Gilbert <i>et al.</i>	
	US25	2004/0248781 A1	12/09/2004	Kerbel, Robert	
	US26	2005/0118180 A1	06/02/2005	Rubinfeld, Joesph	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
	FP14	WO 99/49882 A2	10/07/1999	Eicher, Dorethea	
	FP15	WO 00/21560 A1	04/20/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
		WO 00/24412 A2	05/04/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY	
	FP16				
	FP17	WO 00/58511 A1	10/05/2000	Ludwig Institute for Cancer Research; Helsinki University Licensing Ltd. OY; University of Pittsburgh of the Commonwealth System of Higher Education	
	FP18	WO 00/61186 A1	10/19/2000	Weichselbaum, Ralph R.	
	FP19	WO 00/62798 A2	10/26/2000	St. Elizabeth's Medical Center, Inc.	

576155v1

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.